Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~7 days
Time for 50 % to be eliminated
Steady State
~30.2 days
≈ 4.3 half-lives
Accumulation
×2.0
Cmax at steady state ÷ Cmax first dose
Gone After
~49 days
after last dose
| Hour | % of peak |
|---|---|
| 0 | 100 |
| 117.6 | 61.6 |
| 225.4 | 118.4 |
| 336 | 175 |
| 450.8 | 109 |
| 558.6 | 149.7 |
| 672 | 193.7 |
| 784 | 122.1 |
| 891.8 | 159 |
| 1008 | 198.4 |
| 1117.2 | 126.5 |
| 1234.8 | 156.3 |
| 1352.4 | 96.2 |
| 1470 | 59.2 |
| 1587.6 | 36.5 |
| 1705.2 | 22.4 |
| 1822.8 | 13.8 |
| 1940.4 | 8.5 |
| 2058 | 5.2 |
| 2175.6 | 3.2 |
| 2293.2 | 2 |
Source: Goldstein et al., thymosin beta-4 PK. Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. TB-500: ~7 days.
TB-500 has a reported half-life of about 7 days. Under a twice-weekly dosing schedule, steady state is reached at roughly 4.3 half-lives, about 30 days, and subsequent doses accumulate by a factor of about 3.4 over a single dose. With weekly dosing, the accumulation factor drops to about 2.0.
The blue line plots concentration as a percentage of the first-dose peak. The dashed reference line marks the steady-state peak. After the last dose, concentration drops below 1 % of the peak after about 49 days, seven half-lives.
TB-500 is a synthetic fragment of Thymosin Beta-4, studied for cell migration, tissue repair, and anti-inflammatory effects. Typical doses range from 2 to 5 mg administered two to three times per week. The 7-day half-life produces meaningful accumulation at multi-weekly dosing intervals, and the long clearance window means residual levels persist for weeks after the last dose.